Core Insights - GSK's shares listed in London experienced a decline of nearly 2% following the U.S. FDA's approval of only one out of two treatment combinations involving the company's blood cancer drug [1] Company Summary - The U.S. FDA's decision to approve only one treatment combination limits the potential market and revenue opportunities for GSK's blood cancer drug [1]